Thomas Bock, MD, MBA

Dr. Thomas Bock is a recognized life science leader who built four entrepreneurial organizations that created major impact for both patients and investors and achieved leadership in their fields. Thomas successfully spearheaded new paradigms and fast-growing markets including cancer precision medicine, inherited cancer prevention, and ultra-rare diseases.

Since February 2021, Thomas has been serving as the CEO of Notable, to leverage Notable’s Predictive Precision Medicine Platform for creating and fast-tracking a game-changing and novel class of cancer precision medicines, predictive precision medicines, profoundly improving patient outcomes and the success, speed and cost of drug development.

Previously, Thomas founded and served as CEO of HeritX Inc., a pioneer in inherited cancer prevention through pre-cancer vaccines, immunoprevention, and gene repair, creating the largest prevention pipeline in the industry. Previously, he served as Senior Vice President Medical Affairs on the executive management team of Alexion, building a start-up into a global leader in rare disorders, a growth leader on NASDAQ, and the world’s most innovative life science company, according to Forbes.

Prior to that, Thomas built and led the worldwide Medical Departments of Celgene and Novartis Oncology as their Vice President and Global Head of Medical Affairs. Before that, Thomas served as the medical head of Amgen Europe for hematology and oncology.

Thomas believes in focusing on the most urgent patient needs to earn superior return. He developed and commercialized six lifesaving, paradigm-changing blockbuster medicines in rare diseases, cancer, and inflammation. He turned around two therapies from inferior competitive positions to market leadership and achieved five of the most successful product launches in life science.

Rallying stakeholders across traditional silos, Thomas forged new partnerships across patients, physicians, industry, payers, governments, and investors. In the midst of the COVID pandemic crisis, he co-founded APANDEMIC, a healthcare coalition accelerating the development and access to COVID therapies through digital platforms, artificial intelligence and new government policies, as he presented at Wall Street Journal’s Health Tech Conference 2020.

Thomas started his career as a practicing physician and medical researcher in cell and gene therapies at the Universities of Freiburg and Tübingen in Germany and subsequently as a Fogarty Fellow at the National Human Genome Research Institute of the US National Institutes of Health.

He earned his MD degree at RWTH Aachen University and his MBA at Columbia Business School.

Thomas is a Board Director at Notable Labs (Foster City, CA), the Chair of the Healthcare Advisory Board of Columbia Business School (NY), and an Executive Mentor at Columbia Technology Ventures. He served as Chair of the Board of Directors of HeritX Inc. (Santa Monica, CA), Officer at Rotary International, and Board Chair and President of FORCE, the US patient organization for inherited breast and ovarian cancer.